Myriad Genetics (MYGN) Revenue (2009 - 2026)

Myriad Genetics (MYGN) has reported Revenue for 18 consecutive years, with $200.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue rose 2.3% year-over-year to $200.4 million; the TTM figure through Mar 2026 stood at $829.0 million (changed 0.28% YoY), while the FY2025 annual figure was $824.5 million, down 1.56% from the prior year.
• Revenue slipped to $200.4 million in Q1 2026 per MYGN's latest filing, from $209.8 million in the prior quarter.
• Across five years, Revenue topped out at $213.3 million in Q3 2024 and bottomed at $156.4 million in Q3 2022.
• Historically, Revenue has averaged $193.8 million across 5 years, with a median of $196.6 million in 2023.
• Annual changes were most pronounced in 2022 — Revenue declined 6.52% — and 2023, when it rose 22.7%.
• Myriad Genetics' Revenue stood at $177.8 million in 2022, then rose by 10.57% to $196.6 million in 2023, then increased by 7.12% to $210.6 million in 2024, then retreated by 0.38% to $209.8 million in 2025, then decreased by 4.48% to $200.4 million in 2026.
• Business Quant data shows MYGN's Revenue at $200.4 million in Q1 2026, $209.8 million in Q4 2025, and $205.7 million in Q3 2025.